Evidence map›Paper›PMID 38789267›Full record

ArticleSexually transmitted infections2024

STRIKE-HBV: establishing an HBV screening programme in Kilifi, Kenya-challenges, successes and lessons learnt.

Louise O Downs, Oscar Chirro, Mwanakombo Zaharani, Benson Safari, Dorcas Okanda, George Githinji, Monique I Andersson, Rob Newton, Anthony Etyang, Nadia Aliyan and 1 more

Abstract read
In one paragraph

Article in Sexually transmitted infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Louise O DownsNuffield Department of Medicine, University of Oxford, Oxford, UK louise.downs@exeter.ox.ac.uk.ORCID 0000-0002-6088-4704
Oscar ChirroKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Mwanakombo ZaharaniKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Benson SafariKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Dorcas OkandaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
George GithinjiKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Monique I AnderssonMicrobiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Rob NewtonUganda Virus Research Institute, Entebbe, Wakiso, Uganda.
Anthony EtyangEpidemiology and Demography, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Nadia AliyanKilifi District Hospital, Kilifi, Kenya.
Philippa Clare MatthewsThe Francis Crick Institute, London, UK.ORCID 0000-0002-4036-4269

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectivesChronic hepatitis B infection affects 65 million people in the WHO African Region, but only 4.2% of these are diagnosed and 0.2% on treatment. Here, we present a short report describing establishment of a hepatitis B virus (HBV) programme in Kenya. We share experiences, successes and challenges to support development of future programmes.

methodsFrom March 2023, we began the 'STRIKE-HBV' Study to identify people living with HBV (PLWHB) in Kilifi, Kenya. We employed local staff and provided education and training. Individuals were identified through three routes: (1) we offered free-of-charge HBV testing for all non-pregnant adults attending Kilifi Country Hospital (KCH) outpatient department; (2) we invited PLWHB to reattend for review; and (3) we invited close contacts of PLWHB for screening and vaccination if HBV was negative. All those seropositive for HBV were offered a comprehensive liver health assessment.

resultsWe have established a framework for HBV screening, assessment and linkage to care in Kilifi. Between March 2023 and March 2024, we collected data for 80 PLWHB, comprising (1) screening of 1862 people of whom 30 were seropositive, (2) enrolment of 38 people known to be living with HBV and (3) testing of 97 close contacts of PLWHB, of whom 12 were positive. Among a limited subset with elastography data, we identified 9 of 59 as having significant fibrosis, and a further 6 people had laboratory aspartate transaminase (AST) to platelet ratio index (APRI) scores in keeping with fibrosis. We encountered challenges including procurement delays for hepatitis B surface antigen testing kits and HBV vaccinations, and issues accessing liver elastography.

conclusionsHBV screening was well received by the Kilifi population, has identified people at risk of liver disease progression and is improving linkage to care and vaccination at KCH. Future HBV programmes in WHO Africa can build on this experience as we work to develop accessible, affordable and acceptable care pathways.

Indexed as

Hepatitis B, ChronicMass ScreeningAdultFemaleHepatitis B virusHumansKenyaMaleMiddle AgedYoung AdultHEPATITIS BImplementation SciencePUBLIC HEALTHVIROLOGY

Identifiers

PMID38789267
PMCPMC11287631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.